Technical Analysis for TVGN - Tevogen Bio Holdings Inc.

Grade Last Price % Change Price Change
D 1.42 4.41% 0.06
TVGN closed up 4.41 percent on Wednesday, November 20, 2024, on approximately normal volume.
0 Watchers
Watchlist Portfolio

Trend Table & Recent EOD Trading Signals

ADX Long Term Intermediate Term Short Term
Strong Down Up Down

Date Alert Name Type % Chg
Pocket Pivot Bullish Swing Setup 0.00%
Wide Bands Range Expansion 0.00%
Gapped Up Strength 0.00%
NR7 Range Contraction 4.41%
NR7-2 Range Contraction 4.41%
Narrow Range Bar Range Contraction 4.41%
Wide Bands Range Expansion 4.41%
NR7 Range Contraction 6.77%
NR7-2 Range Contraction 6.77%
Narrow Range Bar Range Contraction 6.77%

   Recent Intraday Alerts

Alert Time
Gapped Up (Full) about 22 hours ago
Rose Above Previous Day's High about 22 hours ago
Rose Above 10 DMA about 22 hours ago
2x Volume Pace about 22 hours ago
1.5x Volume Pace about 22 hours ago

Get a Trading Assistant

Let us help you stay on top of your investments. We will alert you to important technical developments on your portfolio & watchlist.

Profile

Tevogen Bio Holdings Inc. Description

Tevogen Bio is a clinical-stage specialty immunotherapy company harnessing one of nature’s most powerful immunological weapons, CD8+ cytotoxic T lymphocytes, to develop off-the-shelf, genetically unmodified precision T cell therapies for the treatment of infectious diseases, cancers, and neurological disorders, aiming to address the significant unmet needs of large patient populations. Tevogen Leadership believes that sustainability and commercial success in the current era of healthcare rely on ensuring patient accessibility through advanced science and innovative business models. Tevogen has reported positive safety data from its proof-of-concept clinical trial, and its key intellectual property assets are wholly owned by the company, not subject to any third-party licensing agreements. These assets include three granted patents and twelve pending patents, two of which are related to artificial intelligence. Tevogen Bio is driven by a team of highly experienced industry leaders and distinguished scientists with drug development and global product launch experience. Tevogen Bio’s leadership believes that accessible personalized therapeutics are the next frontier of medicine, and that disruptive business models are required to sustain medical innovation.


Classification

Sector: Healthcare
Industry: Biotechnology
Keywords: Cancer Artificial Intelligence Immunotherapy Infectious Diseases Virotherapy Drug Development Neurological Disorders

Is TVGN a Buy, Sell or Hold?

Indicator Bull Case Neutral / Hold Bear Case
50 DMA
200 DMA
ADX Trend
Oversold / Overbought
Relative Strength

Recent News

Date Title
Nov 19 Tevogen Bio Holdings reports Q3 results
Nov 19 Tevogen Bio Reports Third Quarter 2024 Financial Results; Highlights Significantly Improved Financial Position, Unreported Asset Value on Balance Sheets, Efficient Business Model
Nov 14 UPDATE - Tevogen Founder Reflects on Importance of Preserving Shareholder Value While Navigating Growth as it Prepares to File Quarterly Financials
Nov 14 Tevogen Founder Reflects on Importance of Preserving Shareholder Value While Navigating Growth as it Prepares to File Quarterly Financials
Nov 8 Tevogen Bio Nears Finalization of Agreement to Enhance R&D and Manufacturing Capabilities; $36 Million Line of Credit Available for Continued Operations
Nov 5 Tevogen Bio CEO Dr. Ryan Saadi Expresses Gratitude for Prestigious ROI-NJ Recognition, Highlighting Company’s Novel Business Model as Key to Sustainable Success through Patient Affordability
Nov 5 Tevogen Bio Leverages Microsoft Partnership to Deliver Machine Learning Based Target Identification to Address Human Papilloma Virus (HPV), Advancing TVGN 920
Nov 4 Tevogen Bio Announces Appointment of Anthony Tarantino as Patient Advocate to Enhance Community Engagement and Patient Support
Oct 31 Tevogen Bio Expands on Microsoft Partnership to Integrate Machine Learning and AI into Preclinical Processes, Accelerating Drug Development and Reducing Costs
Oct 29 Tevogen Bio Reports Nasdaq Listing Compliance as CEO Reaffirms His Commitment in Bridging the Information Gap About the Company
See more TVGN news...

Indicators

Indicator Value
52 Week High 21.09
52 Week Low 0.2578
Average Volume 20,087,270
200-Day Moving Average 1.98
50-Day Moving Average 1.17
20-Day Moving Average 1.89
10-Day Moving Average 1.45
Average True Range 0.36
RSI (14) 47.64
ADX 30.7
+DI 29.75
-DI 20.99
Chandelier Exit (Long, 3 ATRs) 2.02
Chandelier Exit (Short, 3 ATRs) 2.08
Upper Bollinger Bands 3.05
Lower Bollinger Band 0.73
Percent B (%b) 0.3
BandWidth 123.06
MACD Line 0.01
MACD Signal Line 0.11
MACD Histogram -0.0995
Fundamentals Value
Market Cap 21.21 Million
Num Shares 14.9 Million
EPS 0.09
Price-to-Earnings (P/E) Ratio 15.78
Price-to-Sales 0.00
Price-to-Book 6.87
Pivot Point Level Traditional / Classic Fibonacci Demark Woodie Camarilla
Resistance 4 (R4) 1.96
Resistance 3 (R3) 2.01 1.89 1.87
Resistance 2 (R2) 1.89 1.75 1.86 1.84
Resistance 1 (R1) 1.65 1.66 1.59 1.60 1.81
Pivot Point 1.53 1.53 1.50 1.50 1.53
Support 1 (S1) 1.29 1.39 1.23 1.24 1.03
Support 2 (S2) 1.17 1.30 1.14 1.00
Support 3 (S3) 0.93 1.17 0.97
Support 4 (S4) 0.88